Kazia Therapeutics Reports Encouraging Results in Triple-Negative Breast Cancer Treatment with Paxalisib

Kazia Therapeutics Reports Promising Outcomes in Triple-Negative Breast Cancer Treatment

Kazia Therapeutics Limited, an oncology-focused drug development company headquartered in Sydney, Australia, announces encouraging results from a single-patient expanded access case involving a 40-year-old female diagnosed with triple-negative breast cancer (TNBC). Following her initial diagnosis in April 2023, the patient underwent a rigorous treatment regimen that included neoadjuvant chemotherapy and immunotherapy, culminating in a bilateral mastectomy. The surgery indicated a successful outcome, with no residual cancer detected at that time. However, approximately two years post-surgery, the patient faced a recurrence with metastatic disease affecting her bones and lungs.

In light of the patient's condition, Kazia activated a single-patient expanded-access protocol to administer a combination of immunotherapy, chemotherapy, and its investigational drug, paxalisib. The results have been remarkable; imaging conducted after just three weeks of treatment reveals an impressive 86% reduction in overall tumor burden. This case not only highlights the potential efficacy of paxalisib but also aligns closely with the profiles being studied in Kazia’s ongoing Phase 1b clinical trial. This trial specifically investigates the combination of paxalisib with Keytruda® (pembrolizumab) and chemotherapy, targeting advanced breast cancer, particularly TNBC.

Dr. John Friend, CEO of Kazia Therapeutics, expresses optimism regarding the significant tumor regression observed in this patient. He emphasizes that this case reinforces the company's commitment to advancing its Phase 1b trial, which is designed to assess the safety and preliminary anti-tumor activity of paxalisib. Additionally, the trial aims to explore translational biomarkers associated with circulating tumor cell dynamics, potentially providing insights into treatment responses in future patients. Kazia's lead program, paxalisib, acts as an investigational inhibitor of the PI3K/Akt/mTOR signaling pathway, a critical pathway involved in various cancer types, highlighting the company's focus on innovative cancer therapies.

In conjunction with these promising findings, Kazia Therapeutics continues to engage in vital research aimed at enhancing treatment outcomes for patients with advanced cancers. The company's commitment to exploring novel therapeutic avenues reflects a broader trend in the oncology sector, where personalized treatment approaches are becoming increasingly relevant.